JB

John Ballantyne

North America, North Dakota, United States, Fargo

Description

John Ballantyne is a founder of Agathos Biologics. He co-founded Aldevron with Michael Chambers in 1998 and has been the Chief Scientific Of...

Investor Profile

John Ballantyne has made 10 investments, with 4 in the past 12 months and 50% as lead.

Stage Focus

  • Seed (30%)
  • Series A (20%)
  • Series Unknown (20%)
  • Series B (10%)
  • Angel (10%)
  • Post Ipo Equity (10%)

Country Focus

  • United States (90%)
  • Singapore (10%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Life Science
  • Genetics
  • Medical
  • Oncology
  • Pet
  • Veterinary
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does John Ballantyne frequently co-invest with?

Alix Ventures
North America, California, United States, San Francisco
Co-Investments: 1
KdT Ventures
North America, Texas, United States, Austin
Co-Investments: 1
GSK
North America, Pennsylvania, United States, Kelayres
Co-Investments: 1
8VC
North America, California, United States, San Francisco
Co-Investments: 1
Agilent Technologies
North America, California, United States, Santa Clara
Co-Investments: 1
AME Cloud Ventures
North America, California, United States, Palo Alto
Co-Investments: 1
Digitalis Ventures
North America, New York, United States, New York
Co-Investments: 1
ACVC Partners
North America, Kentucky, United States, California
Co-Investments: 1
Andreessen Horowitz
North America, California, United States, Menlo Park
Co-Investments: 1
TC
North America, New York, United States, New York
Co-Investments: 1

Which angels does John Ballantyne often collaborate with?

MC
North America, North Dakota, United States, Fargo
Shared Deals: 1
Shared Deals: 1
Shared Deals: 1

What are some of recent deals done by John Ballantyne?

VerImmune

Baltimore, Maryland, United States

VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.

BiotechnologyHealth CareOncologyTherapeutics
SeedSep 23, 2024
Amount Raised: $4,500,000
GlucoTrack

Rutherford, New Jersey, United States

GlucoTrack is a medical device manufacturing company that specializes in developing a non-invasive glucose monitoring devices.

Health CareManufacturingMedical DeviceWellness
Post Ipo EquityJul 31, 2024
Amount Raised: $4,000,000
Elegen

San Carlos, California, United States

Elegen is a biotechnology company that develops microfluidic technology.

BiotechnologyHealth CareLife Science
Series BMay 14, 2024
Amount Raised: $35,000,000
Thrixen

Singapore, Central Region, Singapore

Diagnotics, IVD, Point of Care,

BiotechnologyHealth Diagnostics
Series UnknownApr 29, 2024
Amount Raised: $7,000,000
Cytonus Therapeutics

Carlsbad, California, United States

Cytonus is a biotech company combining AI-driven drug discovery together with a class defining drug-delivery platform called the Cargocyte

BiotechnologyHealth CareMedical
Series ANov 3, 2023
Amount Raised: $11,703,095
JURA Bio

Somerville, Massachusetts, United States

Jura Bio is a therapeutics company focused on translating successes in CAR-T to autoimmune disorders.

BiotechnologyGeneticsHealth CareLife ScienceTherapeutics
SeedSep 21, 2023
Amount Raised: $16,100,000
CureLab Oncology

Boston, Massachusetts, United States

CureLab Oncology is a biotechnology company developing revolutionary therapies for oncology patients.

BiotechnologyHealth CareOncologyTherapeutics
Series UnknownDec 22, 2022
Amount Raised: $3,000,000
Myosana Therapeutics

Seattle, Washington, United States

Myosana Therapeutics is a new biotech company developing novel platform technology for non-viral gene delivery.

BiotechnologyTherapeutics
SeedDec 7, 2022
Amount Raised: $5,000,000
Curelab Veterinary

Boston, Massachusetts, United States

Curelab Veterinary operates as an animal-health company that specializes in treating breast cancer in dogs and cats.

Health CareMedicalPetVeterinary
AngelNov 21, 2022
Amount Raised: $2,500,000
Kytopen

Cambridge, Massachusetts, United States

Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.

BiotechnologyGeneticsHealth CareLife Science
Series ASep 28, 2021
Amount Raised: $30,000,000